BioSpace News Archive

PDS Biotechnology Corporation announced that an abstract investigating the ability of PDS0101 in combination with KEYTRUDA® to induce HPV16-specific CD4 and CD8 T cell activation and functionality has been accepted for presentation at the ESMO Targeted Anticancer Therapies Congress 2023 in Paris, March 6-8, 2023.

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the SVB Securities Global Biopharma Conference.

LumiraDx Limited (Nasdaq: LMDX) today announced that it has received an Emergency Use Authorization from the U.S. Food and Drug Administration and validation for use by the UKHSA under the CTDA process for the LumiraDx SARS-CoV-2 & Flu A/B STAR Complete assay that will allow high complexity laboratories to quickly identify and differentiate individuals suspected by a healthcare provider of respiratory viral infection consistent with COVID.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”) today announces the investigator-initiated INSIGHT-003 trial has reached its enrolment target of 20 patients with 1L NSCLC. INSIGHT-003 is the first trial evaluating Immutep’s lead product candidate, eftilagimod alpha (“efti” or “IMP321”) as part of a triple combination therapy with standard-of-care anti-PD-1 therapy and chemotherapy.

The world’s first-in-class candidate substance against idiopathic pulmonary fibrosis, ‘Bersiposocin’, which is under development Daewoong Pharmaceutical, has entered its Phase II clinical administration.

Certa Therapeutics announces ground-breaking clinical trial data for FT011, its novel therapy for the treatment of serious inflammatory and fibrotic diseases.

Bioweg and Ginkgo Bioworks announced a collaboration to optimize the production of bacterial cellulose and to produce novel variants of cellulose with improved performance to serve a variety of end markets.

Opthea Limited announced today that Dr. Megan Baldwin, the Company’s Chief Executive Officer will present at SVB Leerink’s Global Biopharma Conference being held virtually on February 14-16, 2023.

Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced the U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug Application (NDA) for zuranolone in the treatment of major depressive disorder (MDD) and postpartum depression (PPD).

Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug Application (NDA) for zuranolone in the treatment of major depressive disorder (MDD) and postpartum depression (PPD).